摘要
目的 对玻璃体腔注射雷珠单抗后小梁切除术治疗新生血管性青光眼的疗效进行观察。方法 对我院2013年10月~2015年10月收治的10例（10只眼）新生血管性青光眼进行玻璃体腔注射雷珠单抗,8~14 d后进行小梁切除术。并观察虹膜及房角新生血管的消退时间,注射雷珠单抗前后以及行小梁切除术后的眼压变化。结果 玻璃体腔注射雷珠单抗后,在1周内眼虹膜新生血管完全消退的有8只眼,在2周内完全消退的有2只眼。注射雷珠单抗前后眼压变化无统计学意义（P〉0.05）。新生血管消退后行小梁切除术,眼压降低,具有统计学差异（P〈0.05）。结论 利用玻璃体腔注射雷珠单抗并联合小梁切除术在治疗新生血管性青光眼时能有效控制眼压,减少视功能损伤。
Objective To observe the therapeutic effect of trabeculectomy for the treatment of neonatal vascular glaucoma after the injection of the ranibizumab.Methods 10 cases （10 eyes） of neonatal vascular glaucoma were selected from October 2013 to October 2015, all of them were treated with vitreous cavity injection of monoclonal antibody, 8~14 d after were given trabeculectomy. The regression time of the iris and the angle of the newborn blood vessels, intraocular pressure before and after the injection of the ranibizumab, and after trabeculectomy.Results After injection of ranibizumab, the iris neovascularization completely subsided within a week was 8 eyes, 2 eyes were completely subsided in two weeks. There were no signiifcant in intraocular pressure before and after the injection of the ranibizumab （P〉0.05）, the trabeculectomy was given after new blood vessel regression, the intraocular pressure was lower, with signiifcant difference （P〈0.05）.Conclusion The use of vitreous cavity injection of ranibizumab combined with trabeculectomy in the treatment of new vascular glaucoma can effectively control intraocular pressure, it can reduce visual impairment.
出处
《中国继续医学教育》
2016年第24期111-112,共2页
China Continuing Medical Education
